Takeda Re-Files DPP-4 Inhibitor Alogliptin, Plays Up Combo With Actos

As a means of differentiating its just-resubmitted diabetes drug alogliptin, Takeda Pharmaceutical Company Ltd. is playing up a fixed-dose combination with its blockbuster Actos, even though the latter drug has been hit hard by a potential link to bladder cancer.